We are live on ! Find out more
EPZM

Epizyme, Inc

Delisted

EPZM was delisted on the 11th of August, 2022.

105 hedge funds and large institutions have $407M invested in Epizyme, Inc in 2018 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 54 increasing their positions, 19 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

184% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 19

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

7% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 15

1% more funds holding

Funds holding: 104105 (+1)

0% more call options, than puts

Call options by funds: $216K | Put options by funds: $216K

35% less capital invested

Capital invested by funds: $628M → $407M (-$220M)

Holders
105
Holders Change
+1
Holders Change %
+0.96%
% of All Funds
2.34%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
16
Increased
54
Reduced
19
Closed
15
Calls
$216K
Puts
$216K
Net Calls
Net Calls Change
+$85K
Name Holding Trade Value Shares
Change
Change in
Stake
Primecap Management
1
Primecap Management
California
$58.9M -$858K -112,400 -1%
PAI
2
Palo Alto Investors
California
$42.7M +$221K +28,916 +0.4%
NMC
3
NEA Management Company
Maryland
$42.4M +$3.18M +416,667 +6%
RG
4
Redmile Group
California
$40.9M +$33.5M +4,389,089 +195%
BlackRock
5
BlackRock
New York
$32M +$6.34M +830,815 +19%
Vanguard Group
6
Vanguard Group
Pennsylvania
$22.4M -$7.08M -927,035 -20%
Fidelity Investments
7
Fidelity Investments
Massachusetts
$21.4M -$1.48M -193,825 -5%
State Street
8
State Street
Massachusetts
$15.8M +$2.74M +358,154 +16%
Jennison Associates
9
Jennison Associates
New York
$11.6M -$2.47M -324,042 -15%
RSCM
10
Rock Springs Capital Management
Maryland
$9.9M +$2.8M +366,247 +30%
FCMI
11
Foresite Capital Management II
California
$9.6M +$958K +125,500 +9%
VOYA Investment Management
12
VOYA Investment Management
Georgia
$8.52M -$3.09M -404,287 -23%
Norges Bank
13
Norges Bank
Norway
$6.96M
OM
14
Opaleye Management
Massachusetts
$6.93M +$7.06M +925,000 +463%
FCMI
15
Foresite Capital Management III
California
$6.15M +$615K +80,500 +9%
Millennium Management
16
Millennium Management
New York
$5.04M +$5.25M +687,047 +521%
SFM
17
Sphera Funds Management
Israel
$4.62M +$2.67M +350,000 +88%
Northern Trust
18
Northern Trust
Illinois
$4.57M +$544K +71,260 +11%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$4.09M +$935K +122,457 +23%
Marshall Wace
20
Marshall Wace
United Kingdom
$3.58M +$2.02M +264,052 +83%
SI
21
Sofinnova Investments
California
$3.47M +$2.08M +272,337 +93%
Dimensional Fund Advisors
22
Dimensional Fund Advisors
Texas
$3.43M +$2.42M +317,157 +133%
Morgan Stanley
23
Morgan Stanley
New York
$2.93M -$379K -49,667 -9%
TCM
24
Tekla Capital Management
Massachusetts
$2.38M -$760K -99,453 -20%
JP Morgan Chase
25
JP Morgan Chase
New York
$2.32M +$110K +14,400 +4%

EPZM Hedge Fund Activity: Q4 2018 in Review

105 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q4 2018, worth a combined $407M — down 35% from $628M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new EPZM positions and 15 closed out — a net gain of 1 holder — while 54 added to existing stakes and 19 trimmed.

The largest buyer was Redmile Group, adding an estimated $33.5M. The largest seller was Deerfield Management, exiting entirely with an estimated $18.9M sold.

  • 105 institutional investors held Epizyme, Inc (EPZM) as of Q4 2018, up from 104 in Q3 2018.
  • Funds reported $407M of Epizyme, Inc stock for Q4 2018, down 35% quarter-over-quarter.
  • 16 funds opened new Epizyme, Inc positions in Q4 2018 and 15 closed out, a net change of +1 holder.
  • The largest Epizyme, Inc buyer in Q4 2018 was Redmile Group, an estimated $33.5M added.
  • The largest Epizyme, Inc seller in Q4 2018 was Deerfield Management, an estimated $18.9M sold.

Based on aggregated 13F filings for Q4 2018.